SAN ANTONIO – Adding weekly carboplatin to 18 weeks of anthracycline/taxane-based neoadjuvant chemotherapy markedly improved disease-free survival in patients with triple-negative breast cancer, according to updated results from the GeparSixto trial presented at the San Antonio Breast Cancer Symposium.
Dr. Gunter von Minckwitz, president of the German Breast Group, explains in an interview that the nearly 50% reduction in the risk of disease relapse at 3 years seen in the phase II trial has converted him and his coinvestigators to routine use of add-on carboplatin in triple-negative breast cancer patients on neoadjuvant chemotherapy.